Aqueous endocannabinoid concentrations by severity of retinopathy
| 2-AG | AEA | OEA | PEA | Sum | ||
| Female R0M0 | Mean | 0.05* | 0.06 | 0.16 | 0.85 | 1.22 |
| SEM | 0.02 | 0.02 | 0.05 | 0.14 | 0.25 | |
| Male R0M0 | Mean | 0.12 | 0.13 | 0.21 | 0.89 | 1.35 |
| SEM | 0.05 | 0.06 | 0.07 | 0.20 | 0.35 | |
| Female DR | Mean | 0.30* | 0.22 | 0.25 | 0.79 | 1.55 |
| SEM | 0.16 | 0.14 | 0.14 | 0.31 | 0.72 |
Aqueous endocannabinoid levels grouped by both gender and level or diabetic retinopathy. Results were grouped by men and women with no diabetic retinopathy (male R0M0, female R0M0) and women with diabetic retinopathy (female DR). There were no men with diabetic retinopathy.
*Differences of 2-AG levels among women with no retinopathy compared with women with diabetic retinopathy showed significant difference at p=0.025.
AEA, anandamide; 2-AG, 2-arachidonoylglycerol; OEA, oleoylethanolamine; PEA, palmitoylethanolamine.